July 2000
Worldwide Biotech;Jul2000, Vol. 12 Issue 7, p8
Trade Publication
Reports that CytoGenix Inc. has received notification of the publication of international patent applications in its portfolio of antisense molecule expression technology.


Related Articles

  • U.S. PATENT DISCLOSURES.  // BioWorld Today;1/11/2008, Vol. 19 Issue 8, p4 

    This section offers news briefs related to patent disclosures in the U.S. Avicena Group Inc. in Palo Alto, California, has received a patent that covers the use of the company's drug candidates against amyotrophic lateral sclerosis. CellCyte Genetics Corp. in Kirkland, Washington, has received a...

  • OTHER NEWS TO NOTE.  // BioWorld Today;4/5/2007, Vol. 18 Issue 66, p3 

    The article presents news briefs on biotechnology industry in the U.S. The holders of Chromos Molecular Systems Incorporated's convertible, secured bridge loan have demanded repayment of the principal and interest. CytoGenix Inc. has completed a pilot study for its synDNA vaccine for human...

  • CytoGenix discovers new class of antibacterial agents.  // PharmaWatch: Biotechnology;July 2003, Vol. 2 Issue 7, p19 

    Introduces the antibacterial agents developed by CytoGenix Inc. in the U.S. Assessment on the side effects of the drugs; Number of distributors; Prices of the items.

  • OTHER NEWS TO NOTE.  // BioWorld Today;5/11/2007, Vol. 18 Issue 92, p5 

    This section presents news briefs related to the biotechnology industry across the world. Atrium Biotechnologies Inc. in Quebec, changed its name to Atrium Innovations Inc. CytoGenix Inc. in Houston, Texas, and Eurogentec SA in Liege, Belgium, executed a letter of intent regarding the...

  • CYTOGENIX GETS RESEARCH GRANT FROM NIH.  // Biotech Business;May2002, Vol. 15 Issue 5, p2 

    Presents information on the research grant received by biopharmaceutical company CytoGenix Inc. from the National Institutes of Health in the U.S. Scientific background of CytoGenix collaborator Dr. Peter Glazer; Comments given by CytoGenix vice president Dr. Yin Chen about the significance of...

  • CytoGenix completes second round of preclinical anti-sepsis animal studies.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p8 

    Reports on the completion of the second round of preclinical anti-sepsis animal studies conducted by CytoGenix Inc. in the U.S. Efficacy of the firm's DNA antibacterial compound in controlling the growth of wild strain of bacteria; Safety dosage and toxicology of the compound; Development of...

  • Results Update.  // PharmaWatch: Biotechnology;Jan2007, Vol. 6 Issue 1, p7 

    The article offers world news briefs related to drug development. Dynavax Technologies Corp. released the outcome of its clinical trials of hepatitis B virus vaccine Hepsilav. Cell Therapeutics Inc. terminated the Xyotax lung cancer trial because of its inefficiency in treating lung cancer. The...

  • Infectious Diseases News Round-up.  // PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p29 

    The article offers news briefs related to infectious diseases. Sanofi Pasteur has finished shipping 50 million doses of influenza vaccine to the U.S. market, fulfilling its original production plans for the 2006-2007 influenza season. Roche released an update of the vaccine Tamiflu, denying that...

  • Drug Discovery News Headlines May 15, 2003 - June 14, 2003.  // PharmaWatch: Biotechnology;July 2003, Vol. 2 Issue 7, p18 

    Reports developments in the pharmaceutical industry as of July 2003. Terms of the agreement signed between Amgen Inc. and Tularik Inc.; Partnership between Artesian Therapeutics Inc. and Evotec OAI AG; Introduction of the antibacterial agent developed by CytoGenix Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics